🇺🇸 ArriVent BioPharma, Inc.AVBP
Get ArriVent BioPharma, Inc. filings on Telegram the moment they are published.
Follow ArriVent BioPharma, Inc. on TelegramOne tap starts your 30-day free trial. No card needed.
Subject: 8-K Items 7.01, 8.01, 9.01
Overview: The Phase 3 FURVENT trial of firmonertinib failed to meet its primary endpoint of progression free survival by blinded independent central review.
Source: SEC EDGAR · Original filing
Get filings like this in Telegram the moment they are published — for the companies you follow.
Start 30-day trial About Finterest